ScoreWhy is Aurobindo Pharma Ltd. ?
1
Company has a low Debt to Equity ratio (avg) at 0.01 times
2
Poor long term growth as Operating profit has grown by an annual rate 3.26% of over the last 5 years
3
Flat results in Sep 25
- OPERATING CF(Y) Lowest at Rs 1,645.79 Cr
- DPS(Y) Lowest at Rs 0.00
- DPR(Y) Lowest at 0.00%
4
With ROE of 9.8, it has a Fair valuation with a 2 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -2.29%, its profits have fallen by -6.8%
5
High Institutional Holdings at 41.81%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Aurobindo Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aurobindo Pharma for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Aurobindo Pharma
-2.43%
-0.08
28.76%
Sensex
4.55%
0.36
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
5.86%
EBIT Growth (5y)
3.26%
EBIT to Interest (avg)
28.36
Debt to EBITDA (avg)
1.16
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.81
Tax Ratio
31.83%
Dividend Payout Ratio
0
Pledged Shares
17.50%
Institutional Holding
41.81%
ROCE (avg)
14.10%
ROE (avg)
10.48%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
21
Industry P/E
34
Price to Book Value
2.03
EV to EBIT
14.13
EV to EBITDA
10.52
EV to Capital Employed
2.06
EV to Sales
2.15
PEG Ratio
NA
Dividend Yield
0.33%
ROCE (Latest)
14.59%
ROE (Latest)
9.77%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
OPERATING PROFIT TO INTEREST(Q)
Highest at 17.62 times
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 8,891.39 cr
DEBT-EQUITY RATIO(HY)
Lowest at 0.22 times
-5What is not working for the Company
OPERATING CF(Y)
Lowest at Rs 1,645.79 Cr
DPS(Y)
Lowest at Rs 0.00
DPR(Y)
Lowest at 0.00%
Loading Valuation Snapshot...
Here's what is working for Aurobindo Pharma
Operating Profit to Interest - Quarterly
Highest at 17.62 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Cash and Cash Equivalents - Half Yearly
Highest at Rs 8,891.39 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio - Half Yearly
Lowest at 0.22 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Aurobindo Pharma
Operating Cash Flow - Annually
Lowest at Rs 1,645.79 Cr and Fallen
each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (Rs Cr)
Dividend per Share (DPS) - Annually
Lowest at Rs 0.00
in the last five yearsMOJO Watch
Company is distributing lower dividend than previous years
DPS (Rs)
Dividend Payout Ratio (DPR) - Annually
Lowest at 0.00%
in the last five yearsMOJO Watch
Company is distributing lower proportion of profits generated as dividend
DPR (%)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
